• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure

    7/5/23 7:24:00 PM ET
    $VBIV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VBIV alert in real time by email

    Extension of BRII-179 license from VBI Vaccines to global rights bolsters Brii Bio's position to achieve best-in-class HBV functional cure in broad patient populations

    Company also acquires exclusive rights to PreHevbri®, a clinically differentiated, 3-antigen prophylactic vaccine, from VBI in Greater China and Asia Pacific markets

    Company to host conference call on July 6 at 8:30 AM (HKT) / July 5 at 8:30 PM (EST)

    BEIJING and DURHAM, N.C., July 5, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs, today announced that it has entered into license agreements with VBI Vaccines, Inc. ((", VBI", , NASDAQ:VBIV), expanding the companies' collaboration in the hepatitis B virus (HBV) field.

    (PRNewsfoto/Brii Biosciences Limited)

    The newly formed license agreements with VBI signify a substantial expansion in the fight against HBV infection. In the first agreement, Brii Bio's exclusive license for BRII-179 (VBI-2601) is extended to worldwide markets, further establishing its leadership position in pursuing HBV functional cure. A growing body of evidence supports the importance of a strong HBV-specific immune response to achieve a durable HBV functional cure, highlighting a potentially important role for BRII-179 as part of a combination cure strategy.

    Additionally, Brii Bio will acquire exclusive rights to develop and commercialize PreHevbri® in Greater China and Asia Pacific countries including Australia, Indonesia, Malaysia, New Zealand, Philippines, Singapore, South Korea, Thailand and Vietnam, among others. PreHevbri® is a clinically differentiated 3-antigen adult HBV prophylactic vaccine recently approved for use in the United States, European Union/European Economic Area, United Kingdom, Canada, and Israel. Under the terms of the agreements, VBI will receive upfront payments of $15 million including $5 million ring-fenced for manufacturing and supply as well as $3 million equity investment by Brii Bio, contingent on achievement of near-term milestones. VBI is also eligible to receive additional payments based on achievement of regulatory and commercial milestones, as well as royalties. The transaction is subject to certain closing conditions including the satisfactory completion of VBI's financing.

    "We are excited to substantially strengthen our partnership with VBI, expanding our HBV pipeline and reinforcing our commitment to public health by combatting HBV," said Zhi Hong, Ph.D., Chairman and Chief Executive Officer of Brii Bio. "By exploring the combination cure strategies across our portfolio, we aim to produce the most durable curative treatment in the broadest populations of HBV patients. The addition of PreHevbri®, VBI's prophylactic vaccine, to our HBV portfolio allows us to address HBV burdens from prevention to cure and jump-start our commercialization efforts in China and Asia Pacific with high HBV prevalence and population density, unlocking significant revenue potential."

    BRII-179 (VBI-2601) is currently undergoing Phase 2 studies led by Brii Bio in China, evaluating its potential as a key component of a functional cure for chronic HBV patients. Promising results from multiple studies, including Vir Biotechnology's MARCH study and Brii Bio's ongoing Phase 2 trials combining BRII-179 (VBI-2601) with BRII-835 (VIR-2218), have shown a strong correlation between durable HBsAg seroclearance and antibody seroconversion, highlighting the potential of BRII-179 (VBI-2601) as a valuable immunomodulatory component within a functional cure regimen. Brii Bio intends to further evaluate BRII-179 as part of a combination cure strategy in upcoming studies, with a goal to substantially improve upon cure rates achieved with PEG-IFN-α alone and to expand the population of chronic HBV patients eligible for a potential cure.

    PreHevbri®, also known as PreHevbrio® in the U.S. and Canada, PreHevbri® in the European Union/European Economic Area and United Kingdom, and Sci-B-Vac® in Israel, is the only approved 3-antigen HBV vaccine. In pivotal Phase 3 clinical studies, PROTECT and CONSTANT, PreHevbri® showed higher rates of and long-lasting seroprotection across all subjects aged 18+, and 5 to 8 times higher antibody titers compared to Engerix-B, a single-antigen HBV vaccine. Moreover, an integrated safety analysis of both studies demonstrated that PreHevbri® is well tolerated with no unexpected reactogenicity observed.

    Conference Call Information

    A live conference call will be hosted on Thursday, July 6 at 8:30 AM Hong Kong time (Wednesday, July 5 at 8:30 PM U.S. Eastern Time). All participants are required to register in advance of the call. For the registration link, please click here.

    About BRII-179 (VBI-2601)

    BRII-179 (VBI-2601) is a novel recombinant protein-based HBV immunotherapeutic candidate that expresses the Pre-S1, Pre-S2, and S HBV surface antigens, and is designed to induce enhanced B-cell and T-cell immunity. BRII-179 (VBI-2601) is currently being investigated in two Phase 2 clinical trials in combination with BRII-835 (VIR-2218) and PEG-IFN-α as part of a potential functional cure regimen for the treatment of chronic HBV infection.

    About PreHevbri®

    PreHevbri® is the only 3-antigen hepatitis B vaccine, comprised of the three hepatitis B surface antigens of the hepatitis B virus – S, pre-S1, and pre-S2. It is approved for use in the United States, European Union/European Economic Area, United Kingdom, Canada, and Israel. The brand names for this vaccine are: PreHevbrio® (US/Canada), PreHevbri® (EU/EEA/UK), and Sci-B-Vac® (Israel).

    About Hepatitis B

    Hepatitis B viral infection (HBV) is one of the world's most significant infectious disease threats with more than 290 million people infected globally.1 Chronic HBV infection is the leading cause of liver disease and an estimated 820,000 people die of complications from chronic HBV each year.1 HBV is of exceptional concern in China, where 87 million people are infected.2

    About Brii Bio

    Brii Biosciences ("Brii Bio", stock code: 2137.HK) is a biotechnology company developing therapies to address some of the world's most common diseases where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious and central nervous system diseases, the Company is advancing a broad pipeline of unique therapeutic candidates with lead programs to develop a novel functional cure for hepatitis B viral infection (HBV) and first-of-its-kind treatment options for postpartum depression (PPD) and major depressive disorder (MDD). The Company is led by a visionary and experienced leadership team and has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. For more information, visit www.briibio.com.

    1 World Health Organization. (June 2022). Hepatitis B. World Health Organization. Retrieved from https://www.who.int/news-room/fact-sheets/detail/hepatitis-b

    2 World Health Organization. Hepatitis. World Health Organization. Retrieved from https://www.who.int/china/health-topics/hepatitis#:~:text=There%20are%2087%20million%20people,living%20with%20chronic%20hepatitis%20C.

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/brii-biosciences-broadens-its-leadership-in-hepatitis-b-with-a-portfolio-now-addressing-diseases-burdens-from-prevention-to-cure-301870670.html

    SOURCE Brii Biosciences Limited

    Get the next $VBIV alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $VBIV

    DatePrice TargetRatingAnalyst
    11/11/2022$5.00 → $2.00Strong Buy → Outperform
    Raymond James
    3/8/2022$9.00 → $6.00Strong Buy
    Raymond James
    12/29/2021$7.00 → $6.00Buy
    Jefferies
    More analyst ratings

    $VBIV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • VBI Vaccines Provides an Update on its Restructuring Proceedings

      VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided an update on the restructuring proceedings announced on July 30, 2024. U.S. Chapter 15 Filing On August 2, 2024, the United States Bankruptcy Court for the District of Delaware granted provisional relief under Chapter 15 of the U.S. Bankruptcy Code, and scheduled a further hearing to consider the recognition of the July 30, 2024, Ontario Superior Court of Justice (Commercial List) order ("Initial Order"), which granted the company protection under the Companies' Creditors Arrangement Act, R.S.C. 1985, c. C-36, as amended ("C

      8/2/24 4:05:00 PM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives

      VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the Ontario Superior Court of Justice (Commercial List) ("Court") has issued an initial order ("Initial Order") granting the company protection under the Companies' Creditors Arrangement Act, R.S.C. 1985, c. C-36, as amended ("CCAA"). The Initial Order provides for, among other things: (i) a stay of proceeding in favour of VBI, (ii) approval of the DIP Loan (as described below), and (iii) the appointment of Ernst & Young Inc. ("EY") to serve as monitor ("Monitor") in the Court during the restructuring ("Restructuring Pro

      7/30/24 9:55:00 AM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBI Vaccines Announces Results of Annual General Meeting

      VBI Vaccines Inc. (NASDAQ:VBIV) ("VBI" or the "Company"), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the voting results from its annual general meeting of shareholders held on June 25, 2024 (the "Meeting"). The total number of common shares of the Company ("Common Shares") represented by shareholders ("Shareholders") present in person or represented by proxy at the Meeting was an aggregate of 13,879,327 Common Shares, representing 48.39% of VBI's issued and outstanding Common Shares as of the record date for the Meeting, April 26, 2024. The voting results with respect to each of the following eight dir

      6/25/24 4:15:00 PM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VBIV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • VBI Vaccines downgraded by Raymond James with a new price target

      Raymond James downgraded VBI Vaccines from Strong Buy to Outperform and set a new price target of $2.00 from $5.00 previously

      11/11/22 7:30:44 AM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James reiterated coverage on VBI Vaccines with a new price target

      Raymond James reiterated coverage of VBI Vaccines with a rating of Strong Buy and set a new price target of $6.00 from $9.00 previously

      3/8/22 7:08:44 AM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on VBI Vaccines with a new price target

      Jefferies resumed coverage of VBI Vaccines with a rating of Buy and set a new price target of $6.00 from $7.00 previously

      12/29/21 7:23:26 AM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VBIV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Braga Damian

      4 - VBI Vaccines Inc/BC (0000764195) (Issuer)

      7/31/23 5:00:28 PM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Dewilde Michel

      4 - VBI Vaccines Inc/BC (0000764195) (Issuer)

      7/31/23 5:00:30 PM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Beattie Nell

      4 - VBI Vaccines Inc/BC (0000764195) (Issuer)

      7/28/23 6:30:45 PM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VBIV
    SEC Filings

    See more
    • VBI Vaccines Inc. New filed SEC Form 8-K: Bankruptcy or Receivership, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

      8-K - VBI Vaccines Inc/BC (0000764195) (Filer)

      8/2/24 4:05:34 PM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBI Vaccines Inc. New filed SEC Form 8-K: Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Other Events

      8-K - VBI Vaccines Inc/BC (0000764195) (Filer)

      7/30/24 10:28:18 AM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBI Vaccines Inc. New filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - VBI Vaccines Inc/BC (0000764195) (Filer)

      6/25/24 4:15:17 PM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VBIV
    Financials

    Live finance-specific insights

    See more
    • Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results

      Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy Integrating R&D, manufacturing and commercial upsides by acquiring full intellectual property rights of BRII-179 and expanding its manufacturing footprint Prioritizing company resources with a robust cash balance of US$376 million supporting operations until 2027 Company to host a conference call (English session) on March 25 at 8:30 AM ET / 8:30 PM HKT DURHAM, N.C. and BEIJING, March 22, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapie

      3/22/24 7:00:00 AM ET
      $ANTX
      $VBIV
      $VIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • VBI Vaccines Reports Third Quarter 2023 Financial Results

      PreHevbrio (Hepatitis B Vaccine [Recombinant]) global net revenue increased 52% quarter-over-quarter from Q2 to Q3 2023 Continued execution across earlier-stage pipeline, including: Initiation of Phase 2b study of VBI-1901 in recurrent glioblastoma (GBM) patients Interim Phase 1 data announced for pan-coronavirus candidate, VBI-2901 Novel mRNA-launched eVLP platform technology announced VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended September 30, 2023. "In Q3, we were focused on pip

      11/14/23 4:05:00 PM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results

      First patient dosed in a PEG-IFN-α controlled BRII-835 + PEG-IFN-α combination Phase 2 study for HBV functional cure First of several studies to investigate the potential of BRII-179 in enriching patients with strong intrinsic anti-HBsAg responses for curative treatments to start before the end of 2023 Regulatory submissions and preparation for launches of PreHevbri® in APAC countries and regions are underway Near-term revenue opportunities with PreHevbri® and strong balance sheet supporting operations through 2026 Company to host earnings call on August 22 at 8:00 PM ET / August 23 at 8:00 AM HKT and an HBV R&D Day on August 24 from 1:00-2:30 PM HKT DURHAM, N.C. and BEIJING, Aug. 22, 2023 /

      8/22/23 10:00:00 AM ET
      $VBIV
      $VIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $VBIV
    Leadership Updates

    Live Leadership Updates

    See more
    • Brii Biosciences Provides Latest Clinical Development and Corporate Updates

      Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from BRII-835 + PEG-IFN-α study have demonstrated that robust anti-HBs antibody responses at the end of treatment are associated with sustained HBsAg loss 24 weeks post treatment Company owns exclusive global rights of BRII-693 in development for difficult-to-treat carbapenem-resistant Gram-negative bacterial infections Dr. David Margolis appointed as Chief Medical Officer to lead organization's late-stage clinical programs towards commercialization DURHAM, N.C. and BEIJING, July 5, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the

      7/5/23 7:18:00 PM ET
      $ANTX
      $VBIV
      $VIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • VBI Vaccines Appoints Vaughn Himes to Board of Directors

      VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Vaughn B. Himes, Ph.D., Chief Technical Officer of Seagen Inc., has joined VBI's Board of Directors. Dr. Himes has a 30+-year successful track record in biotechnology strategic direction and change management, driving value creation and growth at both small and large biopharmaceutical companies. "Vaughn brings extensive CMC (chemistry, manufacturing, and controls), product development, quality, and strategic business transformation expertise to VBI," said Jeff Baxter, VBI's President and CEO. "In his current and previo

      4/25/23 8:00:00 AM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split

      VBI will continue to heavily prioritize making a difference in both prevention and treatment of hepatitis B (HBV) with PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] and immunotherapeutic candidate VBI-2601 Cost-saving measures expected to reduce quarterly operating expenses and headcount by 30-35% VBI to effect a 1-for-30 reverse stock split of its issued and outstanding common shares – shares are expected to trade on the new split-adjusted basis as of commencement of trading on April 12, 2023 VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced plans to focus the C

      4/4/23 8:00:00 AM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VBIV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by VBI Vaccines Inc. New (Amendment)

      SC 13D/A - VBI Vaccines Inc/BC (0000764195) (Subject)

      4/17/24 4:16:49 PM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by VBI Vaccines Inc. New (Amendment)

      SC 13D/A - VBI Vaccines Inc/BC (0000764195) (Subject)

      11/17/23 6:59:27 PM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by VBI Vaccines Inc. New

      SC 13G - VBI Vaccines Inc/BC (0000764195) (Subject)

      7/20/23 4:16:39 PM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care